The initiation of the PCGP was driven by the recognition that cancer in children is fundamentally different from cancer in adults. Pediatric cancers often have fewer mutations, which makes pinpointing the causative genetic changes particularly challenging. Prior to the PCGP, there was a significant lack of comprehensive genomic data for pediatric cancers, limiting the development of targeted therapies. The project aims to fill this gap by providing a detailed map of the genetic landscape of these cancers.
